NDRA vs PSA · P/E 0.0, $2.6M cap vs rev $4.82B
ENDRA Life Sciences Inc (NDRA) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
ENDRA Life Sciences Inc (NDRA) is a diagnostics & research company listed on US.
PSA (PSA) common stock.
NDRA does not have a complete income-statement cache yet.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
NDRA currently screens at market cap $2.6M and trailing P/E 0.0. PSA currently screens at market cap $0.
Not investment advice. Open the NDRA and PSA stock pages for the full models.
Not investment advice.